Home » Topics » Regulatory » EMA

EMA
RSS

EMA accepts regulatory submission for Forxiga in adults with type 1 diabetes

March 7, 2018

Gene therapy from Meiragtx receives European PRIME disgnation

March 5, 2018

EMA grants orphan drug designation to MTD-119 for hepatocellular carcinoma

March 1, 2018

EMA gives accelerated assessment to Shire's lanadelumab

Feb. 28, 2018

EMA grants orphan drug designation to cannabidiol for tuberous sclerosis

Feb. 28, 2018

EMA committee recommends change to marketing authorization terms for Feraccru

Feb. 26, 2018

BioCryst's Alpivab recommended for approval in E.U. for uncomplicated influenza

Feb. 26, 2018

Amglidia recommended for E.U. approval for neonatal diabetes

Feb. 26, 2018

EMA committee recommends approval of Mylotarg and Bosulif in E.U.

Feb. 26, 2018

EMA committee hands down positive opinion for Kineret in Still's disease

Feb. 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...